DK1175401T3 - Piperazinderivater, der er nyttige som CCR5-antagonister - Google Patents

Piperazinderivater, der er nyttige som CCR5-antagonister

Info

Publication number
DK1175401T3
DK1175401T3 DK00926486T DK00926486T DK1175401T3 DK 1175401 T3 DK1175401 T3 DK 1175401T3 DK 00926486 T DK00926486 T DK 00926486T DK 00926486 T DK00926486 T DK 00926486T DK 1175401 T3 DK1175401 T3 DK 1175401T3
Authority
DK
Denmark
Prior art keywords
derivatives useful
piperazine derivatives
ccr5 antagonists
ccr5
antagonists
Prior art date
Application number
DK00926486T
Other languages
English (en)
Inventor
Bahige M Baroudy
John W Clader
Stuart W Mccombie
Brian A Mckittrick
Michael W Miller
Bernard R Neustadt
Anandan Palani
Elizabeth M Smith
Ruo Steensma
Jayaram R Tagat
Susan F Vice
Mark A Laughlin
Eric Gilbert
Marc A Labroli
Hubert B Josien
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23179892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1175401(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1175401T3 publication Critical patent/DK1175401T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00926486T 1999-05-04 2000-05-01 Piperazinderivater, der er nyttige som CCR5-antagonister DK1175401T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30522699A 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
DK1175401T3 true DK1175401T3 (da) 2005-11-14

Family

ID=23179892

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00926486T DK1175401T3 (da) 1999-05-04 2000-05-01 Piperazinderivater, der er nyttige som CCR5-antagonister

Country Status (31)

Country Link
EP (2) EP1175401B1 (da)
JP (2) JP3722700B2 (da)
KR (1) KR100439358B1 (da)
AR (5) AR023823A1 (da)
AT (2) ATE495154T1 (da)
AU (2) AU780888B2 (da)
BR (1) BR0010304A (da)
CA (1) CA2371583C (da)
CH (1) CH1175401H9 (da)
CL (1) CL2008002737A1 (da)
CO (1) CO5170523A1 (da)
CZ (1) CZ20013940A3 (da)
DE (2) DE60045528D1 (da)
DK (1) DK1175401T3 (da)
EG (1) EG24136A (da)
ES (1) ES2244437T3 (da)
HK (1) HK1039930B (da)
HU (1) HUP0202867A3 (da)
IL (1) IL145741A0 (da)
MY (1) MY128367A (da)
NO (1) NO322045B1 (da)
PE (1) PE20010150A1 (da)
PL (1) PL203116B1 (da)
RU (1) RU2299206C9 (da)
SA (2) SA06270096B1 (da)
SI (1) SI1175401T1 (da)
SK (2) SK287418B6 (da)
TR (1) TR200103214T2 (da)
TW (1) TWI285200B (da)
WO (1) WO2000066558A1 (da)
ZA (1) ZA200108868B (da)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825121B2 (en) * 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
CZ20032636A3 (cs) * 2001-03-29 2003-12-17 Schering Corporation Látky antagonizující CCR5
HUP0400389A3 (en) 2001-03-29 2008-03-28 Schering Corp Aryl oxime-piperazines useful as ccr5 antagonists and pharmaceutical compositions containing them
MXPA04005210A (es) * 2001-11-29 2004-08-19 Schering Corp Procedimiento para la preparacion de composiciones que tienen una cantidad incrementada de sales farmaceuticamente activas de rotameros.
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
JP4671091B2 (ja) * 2002-03-18 2011-04-13 東レ・ファインケミカル株式会社 １−置換−２−メチルピペラジンの製造方法
DE60330323D1 (de) 2002-03-29 2010-01-14 Schering Corp Stereoselektive alkylierung von chirale 2-methyl-4-geschützte piperazinen
US6992189B2 (en) * 2002-03-29 2006-01-31 Schering Corporation Synthesis of piperidine and piperazine compounds as CCR5 antagonists
CA2483253A1 (en) * 2002-04-24 2003-11-06 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
JP2003335737A (ja) 2002-05-21 2003-11-28 Central Glass Co Ltd 光学活性（ｒ）−１−（４−トリフルオロメチルフェニル）エチルアミン
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
EP1570860A4 (en) * 2002-12-13 2009-06-03 Ono Pharmaceutical Co ANTAGONIST AND AGONIST BINDING TO A STRONG BINDING SITE OF THE CHEMOKINE RECEPTOR
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process
RU2006100190A (ru) * 2003-06-13 2006-08-10 Шеринг Акциенгезельшафт (De) Производные хинолиламида в качестве антагонистов ccr-5
JP4605801B2 (ja) 2003-06-30 2011-01-05 シェーリング コーポレイション 肥満治療用のｍｃｈアンタゴニスト
WO2005042517A2 (en) 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CN1946402A (zh) * 2004-02-05 2007-04-11 先灵公司 用作ccr3拮抗剂的哌啶衍生物
KR100863854B1 (ko) * 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제
CN101768129B (zh) 2004-03-05 2012-05-23 日产化学工业株式会社 异*唑啉取代苯甲酰胺化合物的制备中间体
AU2005234596B8 (en) * 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
DK1761542T3 (da) 2004-06-09 2008-04-28 Hoffmann La Roche Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
GB0417804D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EP1836190A2 (en) 2005-01-06 2007-09-26 Schering Corporation Preparation of pharmaceutical salts of piperazine compounds
EP1856098B1 (en) 2005-02-16 2012-08-01 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
MX2007010068A (es) 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
MX2007009946A (es) * 2005-02-16 2007-09-26 Schering Corp Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3.
CA2598460C (en) * 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
CN101146793A (zh) 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
JP4769257B2 (ja) * 2005-02-23 2011-09-07 シェーリング コーポレイション ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
EP1893603B1 (en) 2005-06-02 2009-10-14 F. Hoffmann-La Roche AG Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
EP1942108B1 (en) 2005-10-28 2013-09-04 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
CA2629037A1 (en) * 2005-11-30 2007-06-07 Schering Corporation Compositions comprising a combination of ccr5 and cxcr4 antagonists
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
BRPI0706623A2 (pt) 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007105637A1 (ja) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
EP2057125B1 (en) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
EP2137162B1 (en) * 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
WO2008119663A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
KR20100005730A (ko) 2007-05-07 2010-01-15 노파르티스 아게 유기 화합물
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
MX2010003621A (es) 2007-10-01 2010-04-14 Hoffmann La Roche N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
CA2716838C (en) * 2008-02-29 2014-01-07 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009128947A1 (en) * 2008-04-17 2009-10-22 Concert Pharmaceuticals, Inc. Piperazine derivatives
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
DK2379525T3 (da) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyklisk pyrimidin-4-carboxamider, som CCR2-receptor-antagonister til behandling af inflammation, astma og COPD
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011073154A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
WO2011073155A1 (en) * 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
ES2561353T3 (es) 2012-01-13 2016-02-25 Novartis Ag Sales de un agonista del receptor IP
CN104053659B (zh) 2012-01-13 2016-11-09 诺华股份有限公司 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
EP2956455B1 (en) 2013-02-13 2017-05-17 Novartis AG Ip receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
WO2016028971A1 (en) * 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
PH12022550468A1 (en) 2019-08-28 2023-03-06 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
CA2296314A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
CN1146559C (zh) * 1998-06-30 2004-04-21 先灵公司 毒蕈碱性拮抗剂

Also Published As

Publication number Publication date
AU4500900A (en) 2000-11-17
EP1175401A1 (en) 2002-01-30
EP1632479A3 (en) 2007-05-09
SK15692001A3 (sk) 2002-07-02
HUP0202867A3 (en) 2004-01-28
ZA200108868B (en) 2003-01-27
TWI285200B (en) 2007-08-11
CH1175401H1 (de) 2007-02-15
SA06270096B1 (ar) 2009-02-25
EP1175401B1 (en) 2005-07-20
JP2002543185A (ja) 2002-12-17
TR200103214T2 (tr) 2002-03-21
AR057786A2 (es) 2007-12-19
ES2244437T3 (es) 2005-12-16
AR057106A2 (es) 2007-11-14
WO2000066558A1 (en) 2000-11-09
AU2005202357B2 (en) 2009-04-02
SA00210271B1 (ar) 2006-07-30
KR20020019907A (ko) 2002-03-13
KR100439358B1 (ko) 2004-07-07
DE60021370T2 (de) 2006-04-27
AU780888B2 (en) 2005-04-21
RU2299206C2 (ru) 2007-05-20
MY128367A (en) 2007-01-31
BR0010304A (pt) 2002-02-13
CZ20013940A3 (cs) 2002-04-17
AR057873A2 (es) 2007-12-26
NO20015366L (no) 2002-01-03
RU2299206C9 (ru) 2007-11-20
SK287418B6 (sk) 2010-09-07
HK1039930B (en) 2005-12-09
PE20010150A1 (es) 2001-02-09
SK286641B6 (sk) 2009-03-05
ATE495154T1 (de) 2011-01-15
ATE299865T1 (de) 2005-08-15
CL2008002737A1 (es) 2009-01-16
AR023823A1 (es) 2002-09-04
HUP0202867A2 (hu) 2003-01-28
EG24136A (en) 2008-08-06
PL351388A1 (en) 2003-04-07
DE60045528D1 (de) 2011-02-24
IL145741A0 (en) 2002-07-25
NO20015366D0 (no) 2001-11-02
DE60021370C5 (de) 2007-11-08
PL203116B1 (pl) 2009-08-31
HK1039930A1 (en) 2002-05-17
EP1632479A2 (en) 2006-03-08
CA2371583A1 (en) 2000-11-09
DE60021370D1 (de) 2005-08-25
SI1175401T1 (en) 2005-10-31
CO5170523A1 (es) 2002-06-27
JP2006052225A (ja) 2006-02-23
CH1175401H9 (de) 2007-03-30
JP3722700B2 (ja) 2005-11-30
AR057107A2 (es) 2007-11-14
CA2371583C (en) 2005-09-13
EP1632479B1 (en) 2011-01-12
AU2005202357A1 (en) 2005-06-23
NO322045B1 (no) 2006-08-07

Similar Documents

Publication Publication Date Title
NO20015366L (no) Piperazinderivater som er anvendbare som CCR5-antagonister
DK1175402T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister
NO20021459D0 (no) Piperazin-derivater som 5-HT1B-antagonister
DK1218359T3 (da) Piperazinforbindelser som tachykininantagonister
NO20021450L (no) Cykliske aminforbindelser som CCR5-antagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DK1421075T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister til behandling af HIV
NO20023293D0 (no) Piperidin- og piperazinderivater som virker som 5-HT2A- reseptorantagonister
NO20032142D0 (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1155013T3 (da) Heyterocycliske benzensulfonamidderivater som bradykininantagonister
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK0964863T3 (da) Oxazolidinoner som 5-HT2A-antagonister
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
PT1176144E (pt) Novos derivados de n-triazolilmetil piperazina como antagonistas do receptor da neuroquinina
NO992066D0 (no) Piperazinoderivater som neurokininantagonister
DK1015446T3 (da) 4-(Piperidinyl)-1H-2-benzopyranderivater, der er nyttige som antipsykotiske midler
DK1456197T3 (da) Piperidin-2,6-dioner, som er substitueret heterocyklisk i 3-stillingen
SI1216239T1 (en) Piperazine derivatives as 5-ht1b antagonists
DK1207159T3 (da) Heteroaromatiske derivater som dopamin-D4-receptorantagonister